Ultragenyx to Host Conference Call for Third Quarter 2021 Financial Results and Corporate Update
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) plans to host a conference call on November 2, 2021, at 5 PM ET, to discuss its financial results and corporate update for Q3 2021. The live call can be accessed by phone or via webcast through the company's website. Ultragenyx focuses on developing therapies for rare genetic diseases and has established a diverse portfolio of approved medicines. The company emphasizes efficient drug development to meet urgent patient needs.
- Ultragenyx has a diverse portfolio of approved medicines and treatment candidates.
- The company is committed to addressing diseases with high unmet medical need.
- None.
NOVATO, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel therapies for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Tuesday, November 2, 2021 at 5pm ET to discuss its financial results and corporate update for the quarter ended September 30, 2021.
The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. To participate in the live call by phone, dial (855) 797-6910 (USA) or (262) 912-6260 (International) and enter the passcode 1098326. The replay of the call will be available for one year.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved medicines and treatment candidates aimed at addressing diseases with high unmet medical need and clear biology, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at:
www.ultragenyx.com
Contacts
Ultragenyx Pharmaceutical, Inc.
Investors
Joshua Higa
415-660-0951
Media
Carolyn Wang
415-225-5050
FAQ
When will Ultragenyx release its Q3 2021 financial results?
How can I listen to the Ultragenyx earnings call?
What is the focus of Ultragenyx Pharmaceutical?
Where can I find more information about Ultragenyx?
